dr. J. (Jasper) Stevens


dr. J. (Jasper) Stevens
j.stevens umcg.nl



Profile photo

Jasper Stevens

Research units:

  • Groningen Kidney Center (GKC)



Centre for Human Drug Research



Post-doctoral position

Indiana University-Purdue University Indianapolis, Indiana Clinical and Translational Sciences Institute, Indiana, USA


Research output

  1. van Esdonk MJ, Burggraaf J, van der Graaf PH, Stevens J. Model informed quantification of the feed-forward stimulation of growth hormone by growth hormone-releasing hormone. British Journal of Clinical Pharmacology. 2020 Aug;86(8):1575-1584. https://doi.org/10.1111/bcp.14265
  2. Kuiper SG, Dijkmans AC, Wilms EB, Kamerling IMC, Burggraaf J, Stevens J et al. Pharmacokinetics of fosfomycin in patients with prophylactic treatment for recurrent Escherichia coli urinary tract infection. Journal of Antimicrobial Chemotherapy. 2020 Jul 26;75(11):3278-3285. dkaa294. https://doi.org/10.1093/jac/dkaa294
  3. Stevens J, Wessels MA, Roggeveld J, Koster RA, Dekkers CC, van Gelder MK et al. UHPLC-MS/MS method for iohexol determination in human EDTA and lithium-heparin plasma, human urine and in goat- and pig EDTA plasma. Bioanalysis. 2020 Jul 22;12(14):981-990. https://doi.org/10.4155/bio-2020-0122
  4. Koomen JV, Stevens J, Heerspink HJL. Exposure-response relationships of dapagliflozin on cardiorenal risk markers and adverse events: A pooled analysis of 13 phase II/III trials. British Journal of Clinical Pharmacology. 2020 May 10;86(11):2192-2203. https://doi.org/10.1111/bcp.14318
  5. Goulooze SC, Kruithof AC, Alikunju S, Gautam A, Burggraaf J, Kamerling IMC et al. The effect of food and formulation on the population pharmacokinetics of cholesteryl ester transferase protein inhibitor DRL-17822 in healthy male volunteers. British Journal of Clinical Pharmacology. 2020 Apr 20;86(10):2095-2101. https://doi.org/10.1111/bcp.14297
  6. van Esdonk MJ, Burggraaf J, Dehez M, van der Graaf PH, Stevens J. Quantification of the endogenous growth hormone and prolactin lowering effects of a somatostatin-dopamine chimera using population PK/PD modeling. Journal of pharmacokinetics and pharmacodynamics. 2020 Apr 4;47(3):229-239. https://doi.org/10.1007/s10928-020-09683-3
  7. Kroonen MYAM, Koomen JV, Petrykiv SI, Laverman GD, Heerspink HJL, Stevens J. Exposure-response relationships for the sodium-glucose co-transporter-2 inhibitor dapagliflozin with regard to renal risk markers. Diabetes obesity & metabolism. 2020 Feb 17;22(6):916-921. https://doi.org/10.1111/dom.13976
  8. Koomen JV, Heerspink HJL, Schrieks IC, Schwartz GG, Lincoff AM, Nicholls SJ et al. Exposure and response analysis of aleglitazar on cardiovascular risk markers and safety outcomes: An analysis of the AleCardio trial. Diabetes obesity & metabolism. 2019 Oct 1. https://doi.org/10.1111/dom.13862
  9. Kroonen MYAM, Stevens J, de Zeeuw D, Heerspink HJL. Association between individual cholesterol and proteinuria response and exposure to atorvastatin or rosuvastatin. Diabetes obesity & metabolism. 2019 Sep 30. https://doi.org/10.1111/dom.13849
  10. Joost van Esdonk M, Stevens J, Stuurman FE, de Boon WMI, Dehez M, Hein van der Graaf P et al. The pharmacodynamic effects of a dopamine-somatostatin chimera agonist on the cardiovascular system. Journal of Cardiovascular Pharmacology. 2019 Aug 1;74(2):128-136. https://doi.org/10.1097/FJC.0000000000000695
  11. Kruithof AC, Kumar R, Stevens J, de Kam ML, Gautam A, Alikunju S et al. Effect of Food on the Pharmacokinetics of 2 Formulations of DRL-17822, a Novel Selective Cholesteryl Ester Transfer Protein (CETP) Inhibitor, in Healthy Males. Clinical pharmacology in drug development. 2019 Jun 10;8(8):1042-1052. https://doi.org/10.1002/cpdd.707
  12. van Esdonk MJ, Lindeman I, Okkerse P, de Kam ML, Groeneveld GJ, Stevens J. Population pharmacokinetic/pharmacodynamic analysis of nociceptive pain models following an oral pregabalin dose administration to healthy subjects. CPT: Pharmacometrics & Systems Pharmacology. 2018 Sep;7(9):573-580. https://doi.org/10.1002/psp4.12318
  13. Koomen JV, Stevens J, Mostafa NM, Parving H-H, de Zeeuw D, Heerspink HJL. Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight. Diabetes obesity & metabolism. 2018 Aug;20(8):2019-2022. https://doi.org/10.1111/dom.13312
  14. Van Esdonk MJ, Van Zutphen EJM, Roelfsema F, Pereira AM, Van Der Graaf PH, Biermasz NR et al. How are growth hormone and insulin-like growth factor-1 reported as markers for drug effectiveness in clinical acromegaly research? A comprehensive methodologic review. Pituitary. 2018 Jun;21(3):310-322. https://doi.org/10.1007/s11102-018-0884-4
  15. Ortiz Zacarías NV, Dijkmans AC, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C et al. Fosfomycin as a potential therapy for the treatment of systemic infections: A population pharmacokinetic model to simulate multiple dosing regimens. Pharmacology Research & Perspectives. 2018 Feb;6(1). e00378. https://doi.org/10.1002/prp2.378
  16. Ducore J, Lawrence JB, Simpson M, Boggio L, Bellon A, Burggraaf J et al. Safety and dose-dependency of eptacog beta (activated) in a dose escalation study of non-bleeding congenital haemophilia A or B patients, with or without inhibitors. Haemophilia. 2017 Nov;23(6):844-851. https://doi.org/10.1111/hae.13357
  17. Dijkmans AC, Zacarías NVO, Burggraaf J, Mouton JW, Wilms EB, van Nieuwkoop C et al. Fosfomycin: Pharmacological, Clinical and Future Perspectives. Antibiotics . 2017 Oct 31;6(4). https://doi.org/10.3390/antibiotics6040024
  18. van Esdonk MJ, Burggraaf J, van der Graaf PH, Stevens J. A two-step deconvolution-analysis-informed population pharmacodynamic modeling approach for drugs targeting pulsatile endogenous compounds. Journal of pharmacokinetics and pharmacodynamics. 2017 Aug;44(4):389-400. https://doi.org/10.1007/s10928-017-9526-0
  19. Baakman AC, Alvarez-jimenez R, Rissmann R, Klaassen ES, Stevens J, Goulooze SC et al. An Anti-Nicotinic Cognitive Challenge Model using Mecamylamine in Comparison with the Anti-Muscarinic Cognitive Challenge using Scopolamine. British Journal of Clinical Pharmacology. 2017 Aug;83(8):1676-1687. https://doi.org/10.1111/bcp.13268
  20. Kruithof AC, Watanabe S, Peeters PA, de Kam ML, Zuiker RG, Stevens J et al. Pharmacological interactions between brivaracetam and ethanol in healthy males. Journal of Psychopharmacology. 2017 Jul 1;31(7):915-926. https://doi.org/10.1177/0269881116665326
  21. Okkerse P, van Amerongen G, Stevens J, Butt RP, Gurrell R, Dahan A et al. The use of a battery of pain models to detect analgesic properties of compounds: a two-part four-way crossover study. British Journal of Clinical Pharmacology. 2017 May;83(5):976-990. https://doi.org/10.1111/bcp.13183
  22. Alvarez-Jimenez R, Baakman AC, Stevens J, Goulooze SC, Hart EP, Rissmann R et al. Pharmacokinetics and pharmacodynamics of oral mecamylamine - development of a nicotinic acetylcholine receptor antagonist cognitive challenge test using modelling and simulation. Journal of Psychopharmacology. 2017 Feb 1;31(2):192-203. https://doi.org/10.1177/0269881116681417
  23. Dijkmans AC, Kuiper SG, Burggraaf J, Mouton JW, Wilms EB, Touw DJ et al. Fosfomycine, een oud antibioticum met nieuwe mogelijkheden. Nederlands Tijdschrift voor Geneeskunde. 2017;161(0). D973.
  24. Kanhai K, Goulooze SC, Stevens J, Hay JL, Dent G, Verma A et al. Quantifying Beta-Galactosylceramide Kinetics in Cerebrospinal Fluid of Healthy Subjects Using Deuterium Labeling. Clinical and translational science. 2016 Dec;9(6):321-327. https://doi.org/10.1111/cts.12424
  25. Reijers JAA, van Donge T, Schepers FML, Burggraaf J, Stevens J. Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies. European Journal of Clinical Pharmacology. 2016 Nov;72(11):1343-1352. https://doi.org/10.1007/s00228-016-2101-6
  26. Alvarez-Jimenez R, Groeneveld GJ, van Gerven JMA, Goulooze SC, Baakman AC, Hay JL et al. Model-based exposure-response analysis to quantify age related differences in the response to scopolamine in healthy subjects. British Journal of Clinical Pharmacology. 2016 Oct;82(4):1011-1021. https://doi.org/10.1111/bcp.13031
  27. Peters E, Heuberger JAAC, Tiessen R, van Elsas A, Masereeuw R, Arend J et al. Pharmacokinetic Modeling and Dose Selection in a Randomized, Double-Blind, Placebo-Controlled Trial of a Human Recombinant Alkaline Phosphatase in Healthy Volunteers. Clinical Pharmacokinetics. 2016 Oct;55(10):1227-1237. https://doi.org/10.1007/s40262-016-0399-y
  28. Kervezee L, Gotta V, Stevens J, Birkhoff W, Kamerling I, Danhof M et al. Levofloxacin-Induced QTc Prolongation Depends on the Time of Drug Administration. CPT: Pharmacometrics & Systems Pharmacology. 2016 Sep 1;5(9):466-474. https://doi.org/10.1002/psp4.12085
  29. Teeninga N, Guan Z, Stevens J, Kist-van Holthe JE, Ackermans MT, van der Heijden AJ et al. Population Pharmacokinetics of Prednisolone in Relation to Clinical Outcome in Children With Nephrotic Syndrome. Therapeutic Drug Monitoring. 2016 Aug;38(4):534-545. https://doi.org/10.1097/FTD.0000000000000308
  30. Guan Z, Klumpers LE, Oyetayo O-O, Heuberger J, van Gerven JMA, Stevens J. Pharmacokinetic/pharmaco-dynamic modelling and simulation of the effects of different cannabinoid receptor type 1 antagonists on (9)-tetrahydrocannabinol challenge tests. British Journal of Clinical Pharmacology. 2016 Apr;81(4):713-723. https://doi.org/10.1111/bcp.12852
  31. Kervezee L, Stevens J, Birkhoff W, Kamerling IMC, de Boer T, Dröge M et al. Identifying 24 h variation in the pharmacokinetics of levofloxacin: a population pharmacokinetic approach. British Journal of Clinical Pharmacology. 2016 Feb;81(2):256-268. https://doi.org/10.1111/bcp.12783
  32. Baakman AC, 't Hart E, Kay DG, Stevens J, Klaassen ES, Maelicke A et al. First in human study with a prodrug of galantamine: Improved benefit-risk ratio? Alzheimer's & Dementia: Translational Research & Clinical Interventions. 2016 Jan;2(1):13-22. https://doi.org/10.1016/j.trci.2015.12.003
  33. Spiegelstein O, Stevens J, Van Gerven J, Nathan PJ, Maynard JP, Mayleben DW et al. Pharmacokinetics, pharmacodynamics and safety of CEP-26401, a high-affinity histamine-3 receptor antagonist, following single and multiple dosing in healthy subjects. Journal of Psychopharmacology. 2016;30(10):983-993. https://doi.org/10.1177/0269881116645301
  34. Peters E, Stevens J, Arend J, Guan Z, Raaben W, Laverman P et al. Biodistribution and translational pharmacokinetic modeling of a human recombinant alkaline phosphatase. International Journal of Pharmaceutics. 2015 Nov 10;495(1):122-131. https://doi.org/10.1016/j.ijpharm.2015.08.090
  35. Counsilman CE, Jol-van der Zijde CM, Stevens J, Cransberg K, Bredius RGM, Sukhai RN. Pharmacokinetics of rituximab in a pediatric patient with therapy-resistant nephrotic syndrome. Pediatric Nephrology. 2015 Aug;30(8):1367-1370. https://doi.org/10.1007/s00467-015-3120-8
  36. Kleinloog D, Uit den Boogaard A, Dahan A, Mooren R, Klaassen E, Stevens J et al. Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers. Journal of Psychopharmacology. 2015 Apr;29(4):401-13. https://doi.org/10.1177/0269881115570082
  37. Kleinloog D, Stevens J, Heuberger J, Spinhoven P, van Gerven J. The influence of personality on the sensitivity to subjective effects of Δ9-tetrahydrocannabinol. Psychiatry Research. 2014 Dec 30;220(3):945-953. https://doi.org/10.1016/j.psychres.2014.10.010
  38. Stevens J, Bies RR, Shekhar A, Anand A. Bayesian model of Hamilton Depression Rating Score (HDRS) with memantine augmentation in bipolar depression. British Journal of Clinical Pharmacology. 2013 Mar;75(3):791-798. https://doi.org/10.1111/j.1365-2125.2012.04398.x
  39. Stevens J, Ploeger BA, Hammarlund-Udenaes M, Osswald G, van der Graaf PH, Danhof M et al. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. Journal of pharmacokinetics and pharmacodynamics. 2012 Oct;39(5):463-477. https://doi.org/10.1007/s10928-012-9262-4
  40. Stevens J, Ploeger BA, van der Graaf PH, Danhof M, de Lange ECM. Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. Drug Metabolism and Disposition. 2011 Dec 1;39(12):2275-2282. https://doi.org/10.1124/dmd.111.040782
  41. Stevens J, van den Berg D-J, de Ridder S, Niederländer HAG, van der Graaf PH, Danhof M et al. Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. 2010 Apr 15;878(13-14):969-975. https://doi.org/10.1016/j.jchromb.2010.02.024
  42. Stevens J, Suidgeest E, van der Graaf PH, Danhof M, de Lange ECM. A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. Pharmaceutical Research. 2009 Aug;26(8):1911-1917. https://doi.org/10.1007/s11095-009-9907-1


11th Pharmacometrics Network Benelux Meeting

Jasper Stevens (Invited speaker)


CBG-MEB; Consultant for PK-assessors

Jasper Stevens (Consultant)

15-May-2017 → …

Consultancy related activities in the field of pharmacometrics and pharmacokinetics

Jasper Stevens (Consultant)


Consultancy to make use of the know-how and expertise of the UMCG on the field of human pharmacology applied to drug development

Jasper Stevens (Consultant)


ID: 35668929